Bayer AG (BAYZF)
31.14
+0.02
(+0.08%)
USD |
OTCM |
May 17, 16:00
Bayer Enterprise Value: 21.13B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 21.13B |
| May 16, 2024 | 21.11B |
| May 15, 2024 | 21.78B |
| May 14, 2024 | 21.67B |
| May 13, 2024 | 21.69B |
| May 10, 2024 | 21.25B |
| May 09, 2024 | 20.99B |
| May 08, 2024 | 20.28B |
| May 07, 2024 | 20.49B |
| May 06, 2024 | 20.21B |
| May 03, 2024 | 20.24B |
| May 02, 2024 | 20.46B |
| May 01, 2024 | 19.32B |
| April 30, 2024 | 19.50B |
| April 29, 2024 | 19.17B |
| April 26, 2024 | 19.10B |
| April 25, 2024 | 19.01B |
| April 24, 2024 | 19.00B |
| April 23, 2024 | 19.30B |
| April 22, 2024 | 19.10B |
| April 19, 2024 | 18.25B |
| April 18, 2024 | 17.97B |
| April 17, 2024 | 18.19B |
| April 16, 2024 | 17.46B |
| April 15, 2024 | 18.04B |
| Date | Value |
|---|---|
| April 12, 2024 | 18.90B |
| April 11, 2024 | 19.14B |
| April 10, 2024 | 19.58B |
| April 09, 2024 | 19.59B |
| April 08, 2024 | 19.63B |
| April 05, 2024 | 21.84B |
| April 04, 2024 | 20.68B |
| April 03, 2024 | 20.77B |
| April 02, 2024 | 20.14B |
| April 01, 2024 | 20.60B |
| March 31, 2024 | 20.78B |
| March 28, 2024 | 64.74B |
| March 27, 2024 | 64.73B |
| March 26, 2024 | 63.38B |
| March 25, 2024 | 63.17B |
| March 22, 2024 | 62.84B |
| March 21, 2024 | 62.87B |
| March 20, 2024 | 62.08B |
| March 19, 2024 | 62.14B |
| March 18, 2024 | 62.58B |
| March 15, 2024 | 62.54B |
| March 14, 2024 | 62.29B |
| March 13, 2024 | 63.04B |
| March 12, 2024 | 62.83B |
| March 11, 2024 | 63.30B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
17.46B
Minimum
Apr 16 2024
120.04B
Maximum
Feb 06 2020
59.49B
Average
54.82B
Median
Enterprise Value Benchmarks
| Fresenius Medical Care AG | 21.26B |
| BioNTech SE | 5.173B |
| Affimed NV | 12.80M |
| InflaRx NV | 5.359M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.172B |
| Revenue (Quarterly) | 14.95B |
| Total Expenses (Quarterly) | 11.59B |
| EPS Diluted (Quarterly) | 2.216 |
| Gross Profit Margin (Quarterly) | 60.31% |
| Profit Margin (Quarterly) | 14.53% |
| Earnings Yield | -11.16% |
| Operating Earnings Yield | 28.61% |
| Normalized Earnings Yield | -11.16 |